|Drugs of the Future|
| || |
|Drugs Fut 2007, 32(9): 788|
Copyright 2007 Clarivate Analytics
Revill, P., Serradell, N., Bolos, J., Rosa, E.
|Telaprevir is an investigational oral hepatitis C virus (HCV) protease inhibitor in phase II evaluation in combination with pegylated interferon and ribavirin for the treatment of chronically infected patients with genotype 1 hepatitis C. Interim results from a phase II trial indicated that this drug has the potential to shorten the duration of treatment for some patients with genotype 1 HCV. Additional phase II trials involve the treatment of patients who have failed previous interferon-based treatment, as well as treatment in the absence of ribavirin.|
Full Text: HTML, PDF
| || |